NEWS: Sanders Statement on Proposed Rule by HHS to Cover Anti-Obesity Drugs in Medicare and Medicaid

Press Release

“The good news is that HHS recognizes that vitally important anti-obesity medicines like Wegovy and Zepbound should be made available to all Americans, regardless of income. The bad news is that unless Medicare demands that Novo Nordisk and Eli Lilly substantially reduce the prices for these anti-obesity drugs, Medicare premiums for all seniors would skyrocket. If this proposal is to be financially responsible for seniors and taxpayers, Medicare and Medicaid cannot pay up to 10-15 times more for these drugs than they cost in Europe and other major countries. We cannot allow Medicare and Medicaid to simply be a cash cow for Novo Nordisk and Eli Lilly.”

Source